As I troll The internet and pick up story after story relevant to NFKB, chronic inflammation, the newly discovered biomarker GlycA for cardiac event risk, the huge Japanese study of the elderly (55 to 105), etc., they all cry out for Dr. Mullan's statement in the Rock Creek ad in the biopharmadealmakersnature publication (June 2016): "Much of the scientific excitement about this drug (anatabine) derives from the potentially far-reaching clinical relevance of its mechanism of action, implicated as it is in a wide range of inflammatory and immunological conditions".
"scientific excitement" ???? With RCPIQ at $.0012 ????